SJSimona Jasaityte

Simona Jasaityte

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Simona Jasaityte has a total of 111 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bridging Genetics and Precision Medicine in Parkinson’s Disease through GP2

    by Kajsa Atterling Brolin, Lara M. Lange, Emily Navarro-Jones, Simona Jasaityte, Yuan Ye Beh, Zih-Hua Fang, Hirotaka Iwaki, Lietsel Jones, Christine Klein, Teresa Kleinz, et al.

    In the Global Parkinson’s Genetics Program (GP2) we aim to advance precision medicine by integrating large-scale clinico-genetic data from diverse populations worldwide. We investigated potentially trial-eligible carriers of pathogenic and high-risk GBA1 and LRRK2 variants and conducted a global precision-medicine survey across GP2 sites. Among 65,509 individuals with Parkinson’s disease, we identified 9,019 (13.8%) potentially trial-eligible genetic variant carriers, including 6,789 GBA1 , 2,084 LRRK2 , and 146 dual GBA1-LRRK2 carriers. Individuals were distributed across multiple global regions, many of which currently lack active gene-targeted trials, highlighting a global disparity between relevant variant carriers and the availability of disease modifying treatment trials. GP2’s unified framework supports equitable recruitment for gene-targeted therapeutic studies and helps address critical gaps in Parkinson’s disease genetics and future therapeutic development.

  • Open Access

    Rare but Relevant: Assessing Variants in Dystonia-linked Genes in Parkinson’s Disease

    by Lara M. Lange, Zih-Hua Fang, Laurel Screven, Ai Huey Tan, Roy N. Alcalay, Rim Amouri, Roberta Bovenzi, Matilda Fenn, Joshua L. I. Frost, Joseph Jankovic, et al.

    Background: Dystonia and Parkinson’s disease (PD) show clinical and genetic overlap, but the relevance of dystonia gene variants in PD remains unclear. Objective: To assess the frequency of dystonia-linked pathogenic variants in PD. Methods: We screened sequencing data from 15,738 individuals (7,851 PD, 4,287 atypical parkinsonism, and 3,600 unaffected) from GP2 and AMP-PD for variants in genes linked to isolated dystonia, dystonia-parkinsonism, and myoclonus-dystonia. Results: Pathogenic variants were only identified in PD patients. Forty-five PD individuals (0.57%) carried 26 distinct (likely) pathogenic variants in nine dystonia-linked genes, most frequently in GCH1 , followed by VPS16 . Conclusion: Though rare, pathogenic variants in dystonia-linked genes are present in clinically and pathologically diagnosed PD. Our results reinforce GCH1 as a PD-relevant gene with clinical implications, while variants identified in other genes are rare and of sometimes uncertain relation to the PD phenotype.


  • Open Access

    The Global Landscape of Genetic Variation in Parkinson’s disease: Multi-Ancestry Insights into Established Disease Genes and their Translational Relevance

    by Lara M. Lange, Zih-Hua Fang, Mary B. Makarious, Nicole Kuznetsov, Kajsa Atterling Brolin, Shannon Ballard, Soraya Bardien, Maria Leila Doquenia, Peter Heutink, Henry Houlden, et al.

    Background: The genetic architecture of Parkinson’s disease (PD) varies considerably across ancestries, yet most genetic studies have focused on individuals of European descent, limiting insights into the genetic landscape of PD at a global scale. Methods: We conducted a large-scale, multi-ancestry investigation of causal and risk variants in PD-related genes. Using genetic datasets from the Global Parkinson’s Genetics Program (GP2), we analyzed sequencing and genotyping data from 105,588 individuals, including 63,837 affected and 41,751 unaffected, from eleven different ancestries. Approximately 29% of individuals included were from underrepresented populations. Findings: Our findings revealed shared and ancestry-specific patterns in the prevalence and variant spectrum. Overall, ∼2% of PD individuals carried a causative variant, with substantial variations across ancestries ranging from ∼0·5% in African to ∼7% in Middle Eastern and >10% Ashkenazi Jewish ancestries. Including disease-associated GBA1 and LRRK2 risk variants raised the yield to 13·6%, largely driven by GBA1 , except in East Asians, where LRRK2 risk variants dominated. GBA1 variants were most frequent globally, albeit with substantial differences in frequencies and variant spectra. While GBA1 variants were identified across all ancestries, frequencies ranged from ∼5% in Middle Eastern and South Asian to ∼52% in African ancestry. Similarly, LRRK2 variants showed ancestry-specific enrichment, with p.G2019S most frequently seen in Middle Eastern and Ashkenazi Jewish populations, and risk variants predominating in East Asians. Notably, clinical trials targeting specific genetic variants are currently primarily based in Europe and North America. Another globally PD-relevant gene was PRKN , with variant carriers identified across almost all ancestries. Interpretation: This large-scale, multi-ancestry assessment offers crucial insights into the population-specific genetic architecture of PD. It underscores the critical need for increased ancestral diversity in PD research to improve diagnostic accuracy, enhance our understanding of disease mechanisms across populations, and ensure equitable development and application of emerging precision therapies. Funding: Aligning Science Across Parkinson’s (ASAP) Global Parkinson’s Genetics Program (GP2)


  • Open Access

    Parkinson’s families project: a UK-wide study of early onset and familial Parkinson’s disease

    by Clodagh Towns, Zih-Hua Fang, Manuela M. X. Tan, Simona Jasaityte, Theresa M. Schmaderer, Eleanor J. Stafford, Miriam Pollard, Russel Tilney, Megan Hodgson, Lesley Wu, et al.

    The Parkinson’s Families Project is a UK-wide study aimed at identifying genetic variation associated with familial and early-onset Parkinson’s disease (PD). We recruited individuals with a clinical diagnosis of PD and age at motor symptom onset ≤45 years and/or a family history of PD in up to third-degree relatives. Where possible, we also recruited affected and unaffected relatives. We analysed DNA samples with a combination of single nucleotide polymorphism (SNP) array genotyping, multiplex ligation-dependent probe amplification (MLPA), and whole-genome sequencing (WGS). We investigated the association between identified pathogenic mutations and demographic and clinical factors such as age at motor symptom onset, family history, motor symptoms (MDS-UPDRS) and cognitive performance (MoCA). We performed baseline genetic analysis in 718 families, of which 205 had sporadic early-onset PD (sEOPD), 113 had familial early-onset PD (fEOPD), and 400 had late-onset familial PD (fLOPD). 69 (9.6%) of these families carried pathogenic variants in known monogenic PD-related genes. The rate of a molecular diagnosis increased to 28.1% in PD with motor onset ≤35 years. We identified pathogenic variants in LRRK2 in 4.2% of families, and biallelic pathogenic variants in PRKN in 3.6% of families. We also identified two families with SNCA duplications and three families with a pathogenic repeat expansion in ATXN2, as well as single families with pathogenic variants in VCP, PINK1, PNPLA6, PLA2G6, SPG7, GCH1, and RAB32. An additional 73 (10.2%) families were carriers of at least one pathogenic or risk GBA1 variant. Most early-onset and familial PD cases do not have a known genetic cause, indicating that there are likely to be further monogenic causes for PD.


  • Open Access

    Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease

    by Clodagh Towns, Zih-Hua Fang, Manuela M. X. Tan, Simona Jasaityte, Theresa M. Schmaderer, Eleanor J. Stafford, Miriam Pollard, Russel Tilney, Megan Hodgson, Lesley Wu, et al.

    The Parkinson’s Families Project is a UK-wide study aimed at identifying genetic variation associated with familial and early-onset Parkinson’s disease (PD). We recruited individuals with a clinical diagnosis of PD and age at motor symptom onset ≤ 45 years and/or a family history of PD in up to third-degree relatives. Where possible, we also recruited affected and unaffected relatives. We analysed DNA samples with a combination of single nucleotide polymorphism (SNP) array genotyping, multiplex ligation-dependent probe amplification (MLPA), and whole-genome sequencing (WGS). We investigated the association between identified pathogenic mutations and demographic and clinical factors such as age at motor symptom onset, family history, motor symptoms (MDS-UPDRS) and cognitive performance (MoCA). We performed baseline genetic analysis in 718 families, of which 205 had sporadic early-onset PD (sEOPD), 113 had familial early-onset PD (fEOPD), and 400 had late-onset familial PD (fLOPD). 69 (9.6%) of these families carried pathogenic variants in known monogenic PD-related genes. The rate of a molecular diagnosis increased to 28.1% in PD with motor onset ≤ 35 years. We identified pathogenic variants in LRRK2 in 4.2% of families, and biallelic pathogenic variants in PRKN in 3.6% of families. We also identified two families with SNCA duplications and three families with a pathogenic repeat expansion in ATXN2 , as well as single families with pathogenic variants in VCP , PINK1 , PNPLA6 , PLA2G6 , SPG7 , GCH1 , and RAB32 . An additional 73 (10.2%) families were carriers of at least one pathogenic or risk GBA1 variant. Most early-onset and familial PD cases do not have a known genetic cause, indicating that there are likely to be further monogenic causes for PD.

  • Open Access

    Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)

    by Clodagh Towns, Madeleine Richer, Simona Jasaityte, Eleanor J. Stafford, Julie Joubert, Tarek Antar, Alejandro Martinez-Carrasco, Mary B. Makarious, Bradford Casey, Dan Vitale, et al.

    The Global Parkinson’s Genetics Program (GP2) will genotype over 150,000 participants from around the world, and integrate genetic and clinical data for use in large-scale analyses to dramatically expand our understanding of the genetic architecture of PD. This report details the workflow for cohort integration into the complex arm of GP2, and together with our outline of the monogenic hub in a companion paper, provides a generalizable blueprint for establishing large scale collaborative research consortia.